These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17878957)

  • 1. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
    Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
    Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010.
    López A; Tarragó T; Giralt E
    Expert Opin Ther Pat; 2011 Jul; 21(7):1023-44. PubMed ID: 21539473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new side opening on prolyl oligopeptidase revealed by electron microscopy.
    Tarragó T; Martín-Benito J; Sabidó E; Claasen B; Madurga S; Gairí M; Valpuesta JM; Giralt E
    FEBS Lett; 2009 Oct; 583(20):3344-8. PubMed ID: 19782684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
    Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
    Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of membrane-bound prolyl endopeptidase from brain.
    Tenorio-Laranga J; Venäläinen JI; Männistö PT; García-Horsman JA
    FEBS J; 2008 Sep; 275(17):4415-27. PubMed ID: 18657187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
    Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
    ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of diverse psychopharmacological substances on the activity of brain prolyl oligopeptidase.
    Peltonen I; Männistö PT
    Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):46-54. PubMed ID: 20825390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase.
    Gorrão SS; Hemerly JP; Lima AR; Melo RL; Szeltner Z; Polgár L; Juliano MA; Juliano L
    Peptides; 2007 Nov; 28(11):2146-54. PubMed ID: 17904692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging.
    Moreno-Baylach MJ; Felipo V; Männistö PT; García-Horsman JA
    Neuroscience; 2008 Oct; 156(3):580-5. PubMed ID: 18718510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification by 19F NMR of traditional Chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity.
    Tarragó T; Frutos S; Rodriguez-Mias RA; Giralt E
    Chembiochem; 2006 May; 7(5):827-33. PubMed ID: 16628753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the role of prolyl oligopeptidase in health and disease.
    García-Horsman JA; Männistö PT; Venäläinen JI
    Neuropeptides; 2007 Feb; 41(1):1-24. PubMed ID: 17196652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.
    Tarragó T; Kichik N; Claasen B; Prades R; Teixidó M; Giralt E
    Bioorg Med Chem; 2008 Aug; 16(15):7516-24. PubMed ID: 18650094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters.
    Myöhänen TT; Venäläinen JI; Garcia-Horsman JA; Piltonen M; Männistö PT
    J Comp Neurol; 2008 Apr; 507(5):1694-708. PubMed ID: 18253937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia.
    Prades R; Munarriz-Cuezva E; Urigüen L; Gil-Pisa I; Gómez L; Mendieta L; Royo S; Giralt E; Tarragó T; Meana JJ
    Eur Neuropsychopharmacol; 2017 Feb; 27(2):180-191. PubMed ID: 27986355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of cognitive function.
    Decker MW
    Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
    Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
    Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential expression, activity and nuclear localization of prolyl oligopeptidase protein in the developing rat brain.
    Hannula MJ; Männistö PT; Myöhänen TT
    Dev Neurosci; 2011; 33(1):38-47. PubMed ID: 21160163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.
    Venäläinen JI; Garcia-Horsman JA; Forsberg MM; Jalkanen A; Wallén EA; Jarho EM; Christiaans JA; Gynther J; Männistö PT
    Biochem Pharmacol; 2006 Feb; 71(5):683-92. PubMed ID: 16405869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.
    Jarho EM; Venäläinen JI; Huuskonen J; Christiaans JA; Garcia-Horsman JA; Forsberg MM; Järvinen T; Gynther J; Männistö PT; Wallén EA
    J Med Chem; 2004 Nov; 47(23):5605-7. PubMed ID: 15509157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.